PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Mol Cell Cardiol. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:
PMCID: PMC2692628
NIHMSID: NIHMS100312

Cardioprotective Stimuli Mediate Phosphoinositide 3-Kinase and Phosphoinositide Dependent Kinase 1 Nuclear Accumulation in Cardiomyocytes

Abstract

The phosphoinositide-3-kinase (PI3K) / phosphoinositide dependent kinase 1 (PDK1) signaling pathway exerts cardioprotective effects in the myocardium through activation of key proteins including Akt. Activated Akt accumulates in nuclei of cardiomyocytes suggesting that biologically relevant targets are located in that subcellular compartment. Nuclear Akt activity could be potentiated in both intensity and duration by the presence of a nuclear-associated PI3K / PDK1 signaling cascade as has been described in other non-myocyte cell types. PI3K / PDK1 distribution was determined in vitro and in vivo by immunostaining and nuclear extraction of cultured rat neonatal cardiomyocytes or transgenic mouse hearts. Results show that PI3K and PDK1 are present at a basal level in cardiomyocytes nuclei and that cardioprotective stimulation with atrial natriuretic peptide (ANP) increases their nuclear localization. In comparison, overexpression of nuclear-targeted Akt does not mediate increased translocation of either PI3K or PDK1 indicating that accumulation of Akt does not drive PI3K or PDK1 into the nuclear compartment. Furthermore, PI3K and phospho-Akt473 show parallel temporal accumulation in the nucleus following (MI) infarction challenge. These findings demonstrate the presence of a dynamically regulated nuclear-associated signaling cascade involving PI3K and PDK that presumably influences nuclear Akt activation.

Keywords: Nucleus, PI3K, PDK1, cardiomyocyte, Akt, phosphoinositide

Introduction

Phosphoinositide 3-kinase (PI3K) dependent signaling is a ubiquitous pathway involved in cell growth, proliferation, survival, migration, metabolism and several other biological responses [1]. Class I PI3Ks are activated by receptor tyrosine kinase/cytokine receptor activation (class IA, PI3Kα, β and δ) or by G-protein coupled receptors (Class IB, PI3Kγ), leading to increased phosphatidylinositol (3,4,5) triphosphate (PIP3) levels. Under basal conditions PDK1 and AKT form complexes both in the cytoplasm and at the membrane that is in continuous equilibrium between associated and dissociated forms. AKT inactivity is maintained by interaction between PH domain and kinase domains [2]. Pursuant to receptor stimulation, elevation of PIP3 level induces concentration of molecules possessing PH domains at the plasma membrane promoting interaction between PDK1 and AKT resulting in allowing PDK1 to phosporylate AKT at the T-loop Thr308 residue [3, 4]. Activated AKT remains in activated form upon dissociation from the plasma membrane and accumulates both in the cytoplasm and the nucleus [2]. A second phosphorylation within a C-terminal hydrophobic motif at Ser473 is mediated by the mTOR complex 2 (mTORC2) empowering AKT to be fully activated [5, 6]. Activated Akt is then able to phosphorylate members of the FOXO class of transcription factors and induce their segregation from the nuclear compartment [7].

Upon physiological stimuli, Akt is activated and accumulates in the nucleus of cardiomyocytes [8, 9] preventing apoptosis induced by different kind of pathological insults including ischemia reperfusion [10, 11], volume and/or pressure overload, hypoxia [12], hypoglycemia, or cardiotoxic drugs [13]. Thus, the net result of PI3K activity is enhanced nuclear accumulation of Akt that impacts cardiomyocyte survival, remodeling, and myocardial proliferation [8, 14, 15]. However constitutive AKT activation resulting from adenoviral gene transfer or transgenic expression induces hypertrophy in cardiomyocytes through phosphorylation of target substrate molecules which are predominantly located in the cytoplasm and leads to hypertrophic cardiomyopathy in vivo [16, 17].

Cellular targets of Akt mediating pro-proliferative or anti-apoptotic effects reside within the nuclear compartment [18-20]. Effects of nuclear Akt signaling have been studied by our group through use of a modified Akt expressed in wild-type (non-activated) form targeted to the nucleus by incorporation of a nuclear localization signal (Akt-nuc)[8]. Akt-nuc exerts significant cardioprotective, proliferative, and inotropic effects in cardiomyocytes [15, 21] without induction of hypertrophic response both in vitro and in vivo [14]. Akt-nuc shows these biological activities despite being targeted directly to the nucleus rather than the conventional paradigm of membrane-associated activation and subsequent nuclear accumulation [1]. To explain the inherent activity of Akt-nuc, we hypothesized that a nuclear PI3K / PDK1 signaling network was present in cardiomyocytes and that could be augmented in response to cardioprotective stimulation. Results of our studies reveal that PI3K and PDK1 are present in the nuclei of cardiomyocytes, both in primary neonatal cultures and adult hearts, and that nuclear levels are enhanced upon stimulation by atrial natriuretic peptide (ANP) at anti-apoptotic concentration. Furthermore, PI3K and phospho-Akt473 show parallel temporal accumulation in the nucleus, suggesting the existence of a regulated nuclear PI3K/PDK1 signaling cascade as a previously unrecognized mechanism for increasing nuclear Akt signal intensity and duration in cardiomyocytes following cardioprotective stimulation or cardiomyopathic challenge [8].

Materials and Methods

Mice

All animal protocols have been approved by the Institutional Animal Care Committee of San Diego State University. Hearts were fixed and paraffin embedded or collected for nuclear fractionation. Infarction studies were performed as described in the supplement.

Neonatal rat cardiomyocyte isolation and culture

Neonatal rat ventricular myocytes were isolated as previously described [22] Details of methods are provided in the supplementary section.

Nuclear fractionation of heart tissue and cultured cells

Nuclear fractions were obtained as described before by Camper-Kirby et al. [9]. with a slight modification for cultured cells. Some experiments were performed using an alternative protocol. Details of the methods are reported in in the supplementary section.

Immunostaining and microscopy

Details of procedures for immunolabeling of cultured neonatal rat cardiomyocytes and paraffin sections are provided in the Supplementary methods. Nuclear accumulation in myocardial sections was quantitated as the percentage of positive nuclei per total number of cardiomyocytes observed. Colocalization quantitations were calculated using CoLocalizer Pro version 1.2 (CoLocalization Research Software) analysis software with at least 1000 cells counted in each experiment.

Western blotting

Western blotting was performed using standard techniques as described in the supplementary section.

Statistics

Statistical analysis was performed on at least 3 independent observations in each experimental set by 1-way analysis of variance (ANOVA) or Student's t test, according to the experimental design. If the overall ANOVA p value was significant, pairwise comparisons were performed by Student-Newman-Keuls test. The GraphPad Prism software (version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com) was used for computer analysis. The results are expressed as mean ± standard error of the mean (SEM). The threshold for statistical significance was set as P < 0.05.

Results

ANP stimulation promotes nuclear accumulation of PI3K and PDK1 in cultured neonatal rat cardiomyocytes

Primary cultures of neonatal rat cardiomyocytes (NRCMs) were treated with ANP at 10-9M, a concentration previously shown to mediate nuclear accumulation of Akt [22]. Localization of PI3K and PDK1 were determined by immunofluorescence of cells stained with antibodies to PI3Kp110α (PI3K; catalytic subunit) and to PDK1. Nuclear accumulation was quantified as the percentage of cardiomyocytes with intense nuclear staining per total cardiomyocytes counted (n=3 independent experiments). Accumulation of PI3K in the nuclear compartment increased by 15 to 30 minutes, declining to basal levels after 45 minutes of ANP treatment (Figure 1A and 1B). Under the same conditions PDK1 nuclear accumulation peaked at 30 minutes and returned to basal levels by 60 minutes of treatment (Figure 2A - B). In order to estimate the amount of nuclear translocation of the two kinases induced by ANP, western blots were performed on nuclear and cytosolic fractions of treated and non-treated cells. As observed by immunostaining, PI3K and PDK1 showed similar nuclear accumulation kinetics, increasing significantly compared to control at 30 minutes of ANP 10-9M treatment as previously shown for Akt [22]. Phospho-Akt levels were concomitantly increased by ANP treatment (Figure 3A - B). Since changes in cytosolic levels for PI3K, PDK1 and phospho-Akt kinase were undetectable at this time (Figure 3B), presumably a sub-fraction of the available cytosolic protein pool is concentrated in the nuclear compartment upon stimulation. Further investigations by immunostaining and immunoblot confirmed the previously described increases of nuclear phospho-AktT308 and phospho-AktS473 following ANP treatment. Kinetics of accumulation were similar to that observed for PI3K and PDK1, peaking at 1 hour post treatment (Supplemental Figure 1).

Figure 1
ANP stimulation promotes nuclear accumulation of PI3K in neonatal rat cardiomyocytes
Figure 2
ANP stimulation promotes nuclear accumulation of PDK1 in neonatal rat cardiomyocytes
Figure 3
PI3K, PDK1 and phospho Akt nuclear levels and PI3K activity after ANP treatment

Acute induction of PI3K and PDK1 nuclear localization is mediated by cGMP

Signaling leading to Akt activation lies downstream of an ANP-dependent signaling pathway that is mediated by cGMP [22]. Therefore, robust nuclear accumulation of Akt was induced in the myocardium via cGMP treatment of normal mice to corroborate findings of nuclear PI3K and PDK1 accumulation observed using cultured cardiomyocytes (Figures 1 - -3).3). Nuclear localization of PI3K and PDK1 increased by 98% and 64%, respectively, compared to vehicle injected controls at two hours after injection of cGMP (Supplemental Figure 2A-C). Immunoblot analysis of heart nuclear extracts from cGMP treated mice confirmed these results showing 59% and 24% increases in accumulation of PI3K and PDK1, respectively. No changes were observed in cytosolic fractions (Supplemental Figure 2D).

Nuclear-targeted Akt (Akt-nuc) does not promote higher levels of nuclear PI3K or PDK1

We have previously shown that a wild type Akt construct designed with a nuclear localization sequence becomes activated in the presumed absence of conventional cell membrane translocation to promote PIP3 and PDK-1 interaction [8]. Multiple studies with our Akt-nuc construct show the kinase is functional and exerts potent cardioprotective effects, leaving the issue as to how Akt-nuc achieves active status without cytoplasmic membrane association unresolved. To address the potential influence of overexpressed Akt-nuc upon endogenous PI3K / PDK1 localization allowing for activation, NRCMs were infected with adenoviruses expressing either α-actinin-GFP as control or myc tagged Akt-nuc. Myocytes were fixed and stained for PI3K as well as myc-tag to detect the presence of Akt-nuc at 24 hours post infection. As shown in Supplemental Figure 3A-D, expression of Akt-nuc did not increase nuclear localization of PI3K or PDK1. Although viral infection induces low level PI3K nuclear translocation, no differences were observed between α-actinin-GFP control or Akt-nuc infected NRCMs within nuclear or cytosolic fractions (Supplemental Figure 3E). Immunoblots for PI3K performed on nuclear and cytosolic fractions corroborated staining results. The effect of recombinant adenoviruses expressing dominant negative Akt (Akt-DN) as well as wild-type Akt protein (Akt-wt) on nuclear accumulation of PI3K and PDK1 was also studied in NRCM cultures. Akt-wt-mediated effects were similar to Akt-nuc and did not increase nuclear localization of PI3K or PDK1 (Supplemental Figure 4).

Transgenic mice with cardiac-specific expression of Akt-nuc were examined to support and extend in vitro findings regarding PI3K and PDK1 localization. Nuclei from Akt-nuc hearts showed PI3K levels comparable to that of nontransgenic controls (NTG; Figure 4). However, a marked increase in nuclear PI3K was induced in Akt-nuc mice following intravenous cGMP treatment. Immunohistochemistry of Akt-nuc hearts from mice treated with cGMP showed an increase of myocytes possessing nuclear PI3K labeling relative to control samples treated with vehicle alone (Figure 5A - B). Immunoblots probing myocardial nuclear fractions for PI3K corroborate immunostaining, showing a significant increase in nuclear PI3K levels and no change in cytosolic levels (Figure 5C bottom panel). Thus, forced nuclear accumulation of Akt does not influence nuclear accumulation PDK / PI3K accumulation.

Figure 4
Nuclear PI3K / PDK1 accumulation induced by stimuli such as ANP is mediated upstream of nuclear Akt accumulation
Figure 5
Akt-nuc hearts display a robust response in PI3K translocation to the nucleus upon intravenous cGMP treatment

Myocardial infarction promotes nuclear localization of PI3K concurrent with phospho-Akt473

Myocardial infarction (MI) provokes a reactive survival response in the border zone (BZ) surrounding the damaged tissue. Involvement of PI3K in this reactive signaling response was investigated in mice subjected to myocardial infarction (MI) by coronary artery ligation. Sections were stained to observe PI3K localization in the BZ surrounding the infarct area at 3 and 7 days post surgery. Infarcted myocardium was identified by loss of tropomyosin labeling (Figure 6B-C, infarcted zone, IZ). Increased PI3K nuclear localization was observed within the BZ in both myocytes and non-myocytes (Figures 6A-C, yellow arrows in overlays). Companion serial sections labeled for phospho-Akt473 show nuclear accumulation indicative of Akt activation (Figure 6A-C, right side of panels). In comparison, healthy myocardium of sham operated mice show typical staining for PI3K along myocyte striations with sporadic nuclear staining (Figure 6A).

Figure 6
PI3K nuclear localization parallels nuclear accumulation of phospho-Akt473 following myocardial infarction

Quantitative localization analysis for either PI3K or phospho-AktS473 shows parallel trends in nuclear accumulation with significant increases at both three and seven days after MI (Figure 6D). In sham operated mice the percentage of cells showing PI3K nuclear staining was 9.04% ± 1.83 that remained unchanged throughout the time course of the studies. In comparison, nuclear PI3K immunolabeling increases following MI, increasing at day 3 to 19.50% ± 1.60 and at day 7 to 17.59% ± 3.57. The percentage of cells showing nuclear pS473Akt was higher, with a basal level of 22.25% ± 3.65 in sham operated mice that increases after MI to 48.74% ± 2.08 at day 3 and to 61.75% ± 6.1 at day 7.

Discussion

Recently the paradigm of phospholipids signaling primarily at the plasma membrane has shifted to incorporate an independent nuclear phospholipid cycle [23-25] as well as plasma membrane-associated events being initiated by a nuclear phosphoinositide signaling cascade [26-28]. Nuclear localization of components of the PI3K signaling pathway was first reported in 1994 when PI3K was found to translocate to the nucleus of PC12 cells upon nerve growth factor treatment [26]. Following this initial report, similar results were described in various cell types (HepG2 cells, osteoblast-like MC3T3-E1 cells and others) after stimulation by insulin, insulin-like growth factor 1 (IGF-1) and platelet derived growth factor [29-31]. PI3K is not the only component of this pathway that has been described to shuttle or exist in the nucleus; PDK1, PTEN and Akt have also been shown to translocate to the nucleus upon stimulation or to reside in the nucleus under basal [27, 28, 32].

In the heart, PI3Kα, γ and PTEN are expressed and involved in modulating survival/apoptosis, hypertrophy metabolism and mechanotransduction. Several transgenic and knockout mouse models illustrate the fundamental role of the PI3K pathway in the regulation of myocardial contractility, hypertrophy and cell survival/apoptosis [33]. Cardiac specific overexpression of a constitutively active form of PI3Kα in mice increased heart size via cardiomyocyte enlargement [34], whereas overexpression of a dominant negative form of PI3Kα in the heart decreases heart size with a normal number of smaller myocytes [35]. Gene targeting of the PI3Kγ isoform resulted in increased cardiac contractility without hypertrophy, and a muscle specific deletion of PTEN showed increased heart and cardiomyocyte size with reduced myocardial contractility [35]. A central role for PDK1 in the cardiac PI3K pathway was confirmed by a cardiac specific genetic deletion exhibiting decreased cardiomyocyte size, heart failure and increased sensitivity to hypoxia [36]. Among the primary downstream effectors of the PI3K pathway is Akt, which controls a variety of responses in the heart, such as inhibition of apoptosis, regulation of cell proliferation, metabolism and hypertrophy. Akt targets including glycogen synthase kinase-3β (GSK-3β) [37], mammalian target of rapamycin (mTOR) [38], endothelial nitric oxide synthase (eNOS or NOS3) [39, 40], 6-phospho-fructo-2-kinase (PFK2) [41], c-Raf (a serine/threonine kinase) [42] and several anti-apoptotic effectors [43-47] are localized throughout the cell in cytoplasmic, mitochondrial and nuclear compartments. PI3K activation via Akt enhances cell survival and antagonizes apoptosis in cardiomyocytes [48-50]. Consistent with the regulatory properties of Akt, Akt1 deletion results in mice that are smaller in size and have increased apoptosis [51, 52], while mice overexpressing Akt in the heart display several phenotypes depending on the design used to express the kinase. Three different approaches to overexpress constitutively active Akt in the heart resulted in hypertrophy with reduced [16], normal [17] or enhanced [53] contractility. All of theses approaches have a common feature of predominant membrane-cytoplasmic localization of the overexpressed kinase.

The present study demonstrates that two immediate upstream kinases necessary for Akt activation, PI3K and PDK1, are present in the nucleus of primary cultured neonatal rat cardiomyocytes and in adult mouse cardiac cells. These results extend similar findings from other cell types where most components of the PI3K pathway have been found to be inhabitants of the nucleus or commuters through that compartment [54, 55].

The idea of an autonomous PI3K-Akt pathway present in the nucleus of cardiomyocytes under normal conditions, or being recruited after stimulation, adds another level of regulation for the phosphorylation of Akt and its targets in the nucleus. Several studies have shown that Akt phosphorylation is not required for nuclear translocation [56-58], which makes the idea of nuclear activation of Akt even more appealing [59]. In our study, ANP treatment causes PI3K and PDK1 nuclear accumulation peaking earlier in time (30 minutes) (Figure 1--3)3) than nuclear phospho-Akt (1h) (Supplementary figures 1-3) making it plausible for Akt activation to happen, at least in part, in the nucleus. This temporal pattern of migration to the nucleus has also been shown in MC3T3-E1 mouse calvaria fribroblasts, where IGF-1 and platelet derived growth factor stimulate an increase in nuclear active Akt preceded in time by translocation of PI3K to the nucleus [30, 60].

The mechanism by which PI3K and/or PDK1 enter the nucleus remains obscure, even in non-cardiac cells where these events have been well documented. To date, none of the published literature has temporally separated the nuclear accumulation of both these kinases to examine their relationship, but the literature points to a co-dependence since treatment with PI3K inhibitor LY294002 that inactivates PI3K, leads to lack of PDK1 nuclear accumulation [61]. Nuclear-targeted Akt in the heart has been established to have a protective effect not only in vitro but also in vivo [8, 15, 21, 62]. The fact that Akt-nuc needs to be phosphorylated in order to be active and exert its beneficial role, makes the existence of a nuclear independent activation system in cardiomyocytes (PI3K and PDK1) of key relevance. The presence of PI3K and PDK1 in the nucleus ensures activation of exogenously expressed Akt-nuc and provides a mechanistic basis to explain the activation of nuclear Akt in the absence of the traditional plasma membrane targeting or localization approaches. Phosphatase action represents another possible facet in the regulation of nuclear Akt activity, especially considering that PTEN has already been placed in the nucleus of several types of cells [55]. The relevance of phosphatases in modulation of nuclear Akt awaits future studies that will also delineate the relationship of this nuclear autonomous system in relation to the cytoplasmic compartment to determine which facets of Akt-mediated effects reside within these distinct cellular compartments.

Supplementary Material

Acknowledgments

The authors would like to thank Lexy Walters and Roberto Alvarez for unflagging maintenance of the mouse colony and adenovirus expansion and John Muraski for his technical advice as well as results discussions. This research is supported by NIH grants R01 HL67245 and P01 HL085577 to M.A.S. as well as PO1 AG023071 (Project 3).

Disclosures: Non

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Foukas LC, Okkenhaug K. Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Arch Biochem Biophys. 2003 Jun 1;414(1):13–8. [PubMed]
2. Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA, et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS biology. 2007 Apr;5(4):e95. [PubMed]
3. Cameron AJ, De Rycker M, Calleja V, Alcor D, Kjaer S, Kostelecky B, et al. Protein kinases, from B to C. Biochemical Society transactions. 2007 Nov;35(Pt 5):1013–7. [PubMed]
4. Milburn CC, Deak M, Kelly SM, Price NC, Alessi DR, Van Aalten DM. Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. The Biochemical journal. 2003 Nov 1;375(Pt 3):531–8. [PubMed]
5. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKC[alpha], but Not S6K1. Developmental Cell. 2006;11(6):859–71. [PubMed]
6. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005 Feb 18;307(5712):1098–101. [PubMed]
7. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. The Biochemical journal. 2004 Jun 1;380(Pt 2):297–309. [PubMed]
8. Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res. 2004 Apr 16;94(7):884–91. [PubMed]
9. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KD, Schaefer E, et al. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res. 2001 May 25;88(10):1020–7. [PubMed]
10. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000 Feb 15;101(6):660–7. [PMC free article] [PubMed]
11. Miao W, Luo Z, Kitsis RN, Walsh K. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol. 2000 Dec;32(12):2397–402. [PubMed]
12. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, et al. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999 Dec 7;100(23):2373–9. [PubMed]
13. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation. 2001 Jan 30;103(4):555–61. [PubMed]
14. Tsujita Y, Muraski J, Shiraishi I, Kato T, Kajstura J, Anversa P, et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2006 Aug 1; [PubMed]
15. Gude N, Muraski J, Rubio M, Kajstura J, Schaefer E, Anversa P, et al. Akt promotes increased cardiomyocyte cycling and expansion of the cardiac progenitor cell population. Circ Res. 2006 Aug 18;99(4):381–8. [PubMed]
16. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002 Apr;22(8):2799–809. [PMC free article] [PubMed]
17. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002 Jun 21;277(25):22896–901. [PubMed]
18. Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421–6. [PubMed]
19. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999 Apr 15;398(6728):630–4. [PubMed]
20. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998 Dec 4;273(49):32377–9. [PubMed]
21. Rota M, Boni A, Urbanek K, Padin-Iruegas ME, Kajstura TJ, Fiore G, et al. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ Res. 2005 Dec 9;97(12):1332–41. [PubMed]
22. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC, et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest. 2005 Oct;115(10):2716–30. [PMC free article] [PubMed]
23. Gillooly DJ, Morrow IC, Lindsay M, Gould R, Bryant NJ, Gaullier JM, et al. Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. Embo J. 2000 Sep 1;19(17):4577–88. [PubMed]
24. Irvine RF. Nuclear lipid signalling. Nat Rev Mol Cell Biol. 2003 May;4(5):349–60. [PubMed]
25. Martelli AM, Tabellini G, Borgatti P, Bortul R, Capitani S, Neri LM. Nuclear lipids: new functions for old molecules? J Cell Biochem. 2003 Feb 15;88(3):455–61. [PubMed]
26. Neri LM, Milani D, Bertolaso L, Stroscio M, Bertagnolo V, Capitani S. Nuclear translocation of phosphatidylinositol 3-kinase in rat pheochromocytoma PC 12 cells after treatment with nerve growth factor. Cell Mol Biol (Noisy-le-grand) 1994 Jul;40(5):619–26. [PubMed]
27. Lim MA, Kikani CK, Wick MJ, Dong LQ. Nuclear translocation of 3′-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14006–11. [PubMed]
28. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997 Dec 12;272(50):31515–24. [PubMed]
29. Kim SJ. Insulin rapidly induces nuclear translocation of PI3-kinase in HepG2 cells. Biochem Mol Biol Int. 1998 Sep;46(1):187–96. [PubMed]
30. Martelli AM, Borgatti P, Bortul R, Manfredini M, Massari L, Capitani S, et al. Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha. J Bone Miner Res. 2000 Sep;15(9):1716–30. [PubMed]
31. Zini N, Ognibene A, Bavelloni A, Santi S, Sabatelli P, Baldini N, et al. Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochem Cell Biol. 1996 Nov;106(5):457–64. [PubMed]
32. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999 Apr 15;59(8):1820–4. [PubMed]
33. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004 Aug;37(2):449–71. [PubMed]
34. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J. 2000 Jun 1;19(11):2537–48. [PubMed]
35. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002 Sep 20;110(6):737–49. [PubMed]
36. Mora A, Davies AM, Bertrand L, Sharif I, Budas GR, Jovanovic S, et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. Embo J. 2003 Sep 15;22(18):4666–76. [PubMed]
37. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003 Apr 1;116(Pt 7):1175–86. [PMC free article] [PubMed]
38. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13;103(2):253–62. [PubMed]
39. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999 Jun 10;399(6736):601–5. [PubMed]
40. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999 Jun 10;399(6736):597–601. [PMC free article] [PubMed]
41. Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, Rider MH. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J Mol Cell Cardiol. 2002 Sep;34(9):1091–7. [PubMed]
42. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem. 2002 Aug 23;277(34):31099–106. [PubMed]
43. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002 May 31;296(5573):1655–7. [PubMed]
44. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999 Nov 15;13(22):2905–27. [PubMed]
45. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 2001 Jun;11(3):297–305. [PubMed]
46. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem. 1997 Nov 28;272(48):30491–7. [PubMed]
47. Bijur GN, Jope RS. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem. 2003 Dec;87(6):1427–35. [PMC free article] [PubMed]
48. Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, et al. Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation. 2000 Dec 5;102(23):2873–9. [PubMed]
49. Wu W, Lee WL, Wu YY, Chen D, Liu TJ, Jang A, et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem. 2000 Dec 22;275(51):40113–9. [PubMed]
50. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002 Dec 23;159(6):1029–37. [PMC free article] [PubMed]
51. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001 Sep 1;15(17):2203–8. [PubMed]
52. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001 Oct 19;276(42):38349–52. [PubMed]
53. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12333–8. [PubMed]
54. Neri LM, Borgatti P, Capitani S, Martelli AM. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta. 2002 Oct 10;1584(23):73–80. [PubMed]
55. Lian Z, Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene. 2005 Nov 14;24(50):7394–400. [PubMed]
56. Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev. 2003 Nov 1;17(21):2721–32. [PubMed]
57. Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun. 2005 Jun 24;332(1):167–73. [PubMed]
58. Zhu L, Hu C, Li J, Xue P, He X, Ge C, et al. Real-time imaging nuclear translocation of Akt1 in HCC cells. Biochem Biophys Res Commun. 2007 May 18;356(4):1038–43. [PubMed]
59. Webster KA. Aktion in the nucleus. Circ Res. 2004 Apr 16;94(7):856–9. [PubMed]
60. Borgatti P, Martelli AM, Bellacosa A, Casto R, Massari L, Capitani S, et al. Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Lett. 2000 Jul 14;477(12):27–32. [PubMed]
61. Scheid MP, Parsons M, Woodgett JR. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol. 2005 Mar;25(6):2347–63. [PMC free article] [PubMed]
62. Tsujita Y, Kato T, Sussman MA. Evaluation of left ventricular function in cardiomyopathic mice by tissue Doppler and color M-mode Doppler echocardiography. Echocardiography. 2005 Mar;22(3):245–53. [PubMed]